Skip to main content

Table 2 Risk factors for subsequent MRSA infection in MRSA nasal carrier cohorts

From: Comparison of subsequent infection in methicillin-resistant Staphylococcus aureus nasal carriers between ST72 community-genotype and hospital genotypes: a retrospective cohort study

Variable No. (%) P Adjusted OR (95% CI) P
Patients with subsequent MRSA infection (n = 46) Patients with no subsequent MRSA infection (n = 308)
Female gender 16 (34.8) 122 (39.6) 0.531   
Age, median (IQR) 57.5 (41.0–67.0) 52.5 (5.5–66.0) 0.111   
ST72 MRSA 26 (56.5) 172 (55.8) 0.931   
Reason for nasal MRSA screening
 Transfer from other hospital 24 (52.2) 104 (33.8) 0.015 2.375 (1.094–5.157 0.029
 Pre-operative screening 11 (23.9) 108 (35.1) 0.135   
 MRSA isolated from clinical specimens 23 (50.0) 9 (2.9) <0.001 33.235 (13.102–84.303) <0.001
 Carriage of VRE 2 (4.3) 21 (6.8) 0.752   
 Undergoing HD or CAPD 3 (6.5) 12 (3.9) 0.425   
Admission due to infection other than MRSA infection 17 (37.0) 54 (17.5) 0.002 0.576 (0.240–1.387) 0.219
Comorbidity
 Solid tumor 9 (16.9) 63 (20.5) 0.889   
 Cardiovascular 10 (21.7) 63 (20.5) 0.841   
 Diabetes mellitus 11 (23.9) 47 (15.3) 0.198   
 Liver disease 6 (13.0) 29 (9.4) 0.442   
 Neurologic disease 4 (8.7) 40 (13.0) 0.631   
 Chronic kidney disease 8 (17.4) 32 (10.4) 0.162   
 Solid organ transplantation 2 (4.3) 8 (2.6) 0.625   
 Chronic lung disease 7 (15.2) 8 (2.6) 0.001 4.870 (1.193–19.872) 0.027
 Hematologic malignancy 3 (6.5) 12 (3.9) 0.425   
 CAPD 0 (0.0) 3 (1.0) 1.000   
 HSCT 0 (0.0) 1 (0.3) 1.000   
Severity of underlying disease    0.335   
 Rapidly fatal 3 (6.5) 11 (3.6)    
 Ultimately fatal 26 (56.5) 152 (49.4)    
 Nonfatal 17 (37.0) 145 (47.1)    
  1. MRSA methicillin-resistant Staphylococcus aureus, OR odds ratio, IQR Interquartile range, ST sequence type, VRE vancomycin-resistant Enterococcus, HD hemodialysis, CAPD continuous ambulatory peritoneal dialysis, HSCT hematopoietic stem cell transplantation
\